Oncotarget

Research Perspectives:

Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models

Lionel M.L. Chow and Suzanne J. Baker _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:67-77. https://doi.org/10.18632/oncotarget.425

Metrics: PDF 1418 views  |   HTML 1969 views  |   ?  


Abstract

Lionel M.L. Chow1 and Suzanne J. Baker2

1Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229.

3Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, TN 38105.

Received: January 9, 2012; Accepted: January 21, 2012; Published: January 25, 2012;

Keywords: glioblastoma, astrocytoma, mouse model, PI3K pathway

Correspondence:

Lionel Chow, email:

Suzanne Baker, email:

Abstract

High-grade astrocytoma remains a significant challenge to the clinician and researcher alike. Intense study of the molecular pathogenesis of these tumors has allowed identification of frequent genetic alterations and critical core pathways in this disease. The use of novel mouse genetic tools to study the consequence of specific mutations in brain has led to the development of multiple representative genetically engineered mouse models that provided novel insights into gliomagenesis. As we learn more about the biology of high-grade astrocytoma from the study of these models, we anticipate that our improved understanding will eventually lead to greater success in clinical trials and improved outcome for patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 425